FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1997538260> ?p ?o ?g. }

• W1997538260 endingPage "126" @default.
• W1997538260 startingPage "115" @default.
• W1997538260 abstract "At present, sipuleucel-T represents the only approved immunotherapy for prostate cancer. Sipuleucel-T is an autologous cellular therapy, which primes autologous antigen-presenting cells against the prostatic acid phosphatase (PAP) antigen. For patients with metastatic castrate-resistant prostate cancer (CRPC) who are asymptomatic or minimally symptomatic, sipuleucel-T monotherapy is one of the standard of care treatment options pre- or postdocetaxel. With the approval of new treatments, including abiraterone and enzatutamide, sequencing and combination of these treatments with sipuleucel-T represent unanswered questions facing the field. Whereas steroids that are coadministered with abiraterone and chemotherapy have long been thought to be immunosuppressive, early results show that concurrent abiraterone and prednisone does not significantly impact the ability to develop immune responses to this treatment. Additional clinical data are needed to elucidate optimal sequencing of therapeutic agents in CRPC. Several novel immunotherapies are currently in development, and enrollment in clinical trials should be considered. These include PROSTVAC-VF, a viral vaccine that encodes PSA and T-cell costimulatory molecules, which is currently undergoing phase III clinical trials. DNA plasmid-based vaccines targeting different antigens, including PAP, also are under investigation. Immune checkpoint blockade with ipilimumab, a monoclonal antibody against CTLA-4, which is approved for metastatic melanoma, also is being evaluated. Whereas this treatment failed to show significant improvement in overall survival in CRPC patients treated with docetaxel, results from a phase III trial in the predocetaxel setting are pending. Conventional therapies for prostate cancer, such as radiation and hormonal therapy, may have immunomodulatory effects. Future areas for research include the sequencing and combination of immunotherapies as well as other conventional therapies." @default.
• W1997538260 created "2016-06-24" @default.
• W1997538260 creator A5050947633 @default.
• W1997538260 creator A5073970384 @default.
• W1997538260 date "2014-01-10" @default.
• W1997538260 modified "2023-09-27" @default.
• W1997538260 title "Beyond Sipuleucel-T: Immune Approaches to Treating Prostate Cancer" @default.
• W1997538260 cites W1962181166 @default.
• W1997538260 cites W1966617868 @default.
• W1997538260 cites W1967434920 @default.
• W1997538260 cites W2025421597 @default.
• W1997538260 cites W2028813021 @default.
• W1997538260 cites W2057968168 @default.
• W1997538260 cites W2057977955 @default.
• W1997538260 cites W2066611673 @default.
• W1997538260 cites W2069640477 @default.
• W1997538260 cites W2071124717 @default.
• W1997538260 cites W2093200928 @default.
• W1997538260 cites W2097995306 @default.
• W1997538260 cites W2101653483 @default.
• W1997538260 cites W2102031533 @default.
• W1997538260 cites W2102143045 @default.
• W1997538260 cites W2103959341 @default.
• W1997538260 cites W2108789863 @default.
• W1997538260 cites W2114156781 @default.
• W1997538260 cites W2118982164 @default.
• W1997538260 cites W2121290865 @default.
• W1997538260 cites W2124730679 @default.
• W1997538260 cites W2127387126 @default.
• W1997538260 cites W2129153120 @default.
• W1997538260 cites W2130846254 @default.
• W1997538260 cites W2137467802 @default.
• W1997538260 cites W2137545053 @default.
• W1997538260 cites W2143163879 @default.
• W1997538260 cites W2148643283 @default.
• W1997538260 cites W2149752186 @default.
• W1997538260 cites W2153935963 @default.
• W1997538260 cites W2155846302 @default.
• W1997538260 cites W2160834915 @default.
• W1997538260 cites W2161817637 @default.
• W1997538260 cites W2169258216 @default.
• W1997538260 cites W2170805832 @default.
• W1997538260 cites W2171451762 @default.
• W1997538260 cites W2298617717 @default.
• W1997538260 cites W2999010139 @default.
• W1997538260 doi "https://doi.org/10.1007/s11864-013-0267-z" @default.
• W1997538260 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4523381" @default.
• W1997538260 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24402184" @default.
• W1997538260 hasPublicationYear "2014" @default.
• W1997538260 type Work @default.
• W1997538260 sameAs 1997538260 @default.
• W1997538260 citedByCount "13" @default.
• W1997538260 countsByYear W19975382602014 @default.
• W1997538260 countsByYear W19975382602015 @default.
• W1997538260 countsByYear W19975382602016 @default.
• W1997538260 countsByYear W19975382602017 @default.
• W1997538260 countsByYear W19975382602018 @default.
• W1997538260 countsByYear W19975382602019 @default.
• W1997538260 countsByYear W19975382602023 @default.
• W1997538260 crossrefType "journal-article" @default.
• W1997538260 hasAuthorship W1997538260A5050947633 @default.
• W1997538260 hasAuthorship W1997538260A5073970384 @default.
• W1997538260 hasBestOaLocation W19975382602 @default.
• W1997538260 hasConcept C121608353 @default.
• W1997538260 hasConcept C126322002 @default.
• W1997538260 hasConcept C143998085 @default.
• W1997538260 hasConcept C203014093 @default.
• W1997538260 hasConcept C2776490512 @default.
• W1997538260 hasConcept C2777701055 @default.
• W1997538260 hasConcept C2777899217 @default.
• W1997538260 hasConcept C2778971682 @default.
• W1997538260 hasConcept C2780192828 @default.
• W1997538260 hasConcept C2780851360 @default.
• W1997538260 hasConcept C2781190966 @default.
• W1997538260 hasConcept C2781406297 @default.
• W1997538260 hasConcept C2781433595 @default.
• W1997538260 hasConcept C535046627 @default.
• W1997538260 hasConcept C71924100 @default.
• W1997538260 hasConcept C8891405 @default.
• W1997538260 hasConceptScore W1997538260C121608353 @default.
• W1997538260 hasConceptScore W1997538260C126322002 @default.
• W1997538260 hasConceptScore W1997538260C143998085 @default.
• W1997538260 hasConceptScore W1997538260C203014093 @default.
• W1997538260 hasConceptScore W1997538260C2776490512 @default.
• W1997538260 hasConceptScore W1997538260C2777701055 @default.
• W1997538260 hasConceptScore W1997538260C2777899217 @default.
• W1997538260 hasConceptScore W1997538260C2778971682 @default.
• W1997538260 hasConceptScore W1997538260C2780192828 @default.
• W1997538260 hasConceptScore W1997538260C2780851360 @default.
• W1997538260 hasConceptScore W1997538260C2781190966 @default.
• W1997538260 hasConceptScore W1997538260C2781406297 @default.
• W1997538260 hasConceptScore W1997538260C2781433595 @default.
• W1997538260 hasConceptScore W1997538260C535046627 @default.
• W1997538260 hasConceptScore W1997538260C71924100 @default.
• W1997538260 hasConceptScore W1997538260C8891405 @default.
• W1997538260 hasIssue "1" @default.
• W1997538260 hasLocation W19975382601 @default.
• W1997538260 hasLocation W19975382602 @default.

• next